FLOW Trial: Semaglutide Reduces Kidney Risk in Patients With Diabetes and Obesity

When the FLOW study was presented at ENDO 2026, the medical community paid attention. It is not every day that a clinical trial brings numbers this clear about organ protection. Semaglutide, the active ingredient behind medications like Ozempic and Wegovy, showed the ability to reduce kidney event risk by 24% in patients living with type 2 diabetes and obesity. This data changes the way doctors and patients think about treating conditions that, when combined, quietly damage the kidneys over years.

The kidneys are organs that do not complain. When they start losing function because of diabetes or high blood pressure, the person generally feels nothing. That is the problem. Millions of people walk around with ongoing kidney injury without knowing it. The FLOW trial was designed precisely to measure the impact of a pharmacological intervention on this invisible deterioration. More than 3,500 patients from dozens of countries participated, all with a confirmed diagnosis of type 2 diabetes and early to moderate chronic kidney disease.

Researchers divided participants into two groups. One received injectable semaglutide once a week, at a 1 mg dose. The other received placebo. Everyone continued regular medical follow-up and their usual treatment for diabetes and blood pressure. After a follow-up period exceeding two years, the group that took semaglutide showed not only the 24% reduction in risk of serious kidney events, but also better glycemic control and significant weight loss compared to the placebo group.

The definition of a serious kidney event in the study included abrupt loss of kidney function, progression to end-stage kidney disease, and death from kidney-related causes. Each of these outcomes was less frequent in the group that received the medication. Researchers highlighted that the benefit appeared regardless of how much weight the patient lost, which suggests that the kidney protection mechanism goes beyond simple fat mass reduction.

This point is important because it raises discussion about how semaglutide acts in the body. The molecule mimics a hormone called glucagon-like peptide-1, or GLP-1. When administered, it increases insulin secretion after meals, reduces glucagon production, slows stomach emptying, and acts on hunger centers in the brain. But FLOW suggests there is also a direct effect on inflammation in the blood vessels that supply the kidneys and on fibrosis of kidney tissue. Researchers are still putting together the complete puzzle of the mechanisms, but the clinical data is robust enough to already be changing medical practice.

For people with diabetes and obesity, protecting the kidneys needs to be a priority from the moment of diagnosis. Progression of chronic kidney disease is slow, but irreversible once it reaches advanced stages. Dialysis and transplant are the only alternatives when the kidney stops working. Therefore, any strategy that slows this trajectory deserves to be considered seriously.

Follow-up for anyone using semaglutide requires attention to some practical points. The medication starts at a low dose to reduce side effects like nausea. The doctor adjusts gradually until reaching the dose that offers the best result for that patient. Blood and urine tests should be repeated periodically to monitor not only blood sugar, but also kidney function. This ongoing follow-up is what makes it possible to adjust treatment before bigger problems develop.

Managing a condition like type 2 diabetes alongside obesity involves daily decisions about nutrition, physical activity, medication, and tests. Many people feel they need support to organize all of this. The Ozempro app was developed to help exactly with this routine. Through a quiz available at that link, the user receives personalized follow-up suggestions that take into account their clinical profile and each person's goals. The idea is to turn information into practical action, without complication.

Keeping the kidneys functioning well for more years is a goal worth pursuing. The FLOW trial brought concrete evidence that semaglutide can help with that when prescribed by a doctor and used with regular follow-up. The next step is talking to your healthcare team to understand whether this option makes sense for your specific case.